Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

被引：9

作者：

Kaseb, Ahmed Omar

Cao, Hop Sanderson Tran

Mohamed, Yehia, I

Qayyum, Aliya

Vence, Luis M.

Blando, Jorge M.

Singh, Shalini

Lee, Sunyoung S.

Raghav, Kanwal Pratap Singh

Altameemi, Lina

Rashid, Asif

Vauthey, Jean-Nicolas

Carter, Kristen

Tzeng, Ching-Wei David

Chun, Yun Shin

Yao, James C.

Wolff, Robert A.

Allison, James Patrick

Sharma, Padmanee

机构：

[1] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA

[4] MDAndersson, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4599

引用

页数：2